Avencia Sanchez-Mejias

Avencia Sánchez-Mejías is CEO and co-founder of Integra Therapeutics, a biotechnology company developing next-generation gene writing tools for advanced therapies. Since 2020, she has led the company’s growth and advancement of its FiCAT platform, which combines CRISPR precision with high-capacity DNA integration for cell and gene therapy applications. Sánchez-Mejías has a scientific background in molecular oncology, clinical genetics, and synthetic biology, with research experience in Spain, Singapore, and the United States. Prior to founding Integra, she was a senior researcher at Pompeu Fabra University in Barcelona.